A Double-Blind Randomized Placebo-Controlled Trial of Orlistat for the Treatment of Nonalcoholic Fatty Liver Disease

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 5, 2006, Pages 639-644

  Zelber Sagi, Shira ^a   Kessler, Ada ^a   Brazowsky, Eli ^a   Webb, Muriel ^a   Lurie, Yoav ^a   Santo, Moshe ^a   Leshno, Moshe ^a   Blendis, Laurence ^a   Halpern, Zamir ^a   Oren, Ran ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE; INSULIN; LIPID; LIVER ENZYME; PLACEBO; TETRAHYDROLIPSTATIN;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FIBROSIS; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; ULTRASOUND; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; BIOPSY, NEEDLE; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LACTONES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER; WEIGHT LOSS;

EID: 33646483917     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.02.004     Document Type: Article

References (33)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
2. Foreyt J., and Goodrick K. The ultimate triumph of obesity. Lancet 346 (1995) 134-135
3. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease. a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
4. Andersen T., Gluud C., Franzmann M.B., et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12 (1991) 224-229
5. Dixon J.B., Bhathal P.S., Hughes N.R., et al. Nonalcoholic fatty liver disease. improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
6. Eriksson S., Eriksson K.F., and Bondesson L. Nonalcoholic steatohepatitis in obesity. a reversible condition. Acta Med Scand 220 (1986) 83-88
7. Luyckx F.H., Desaive C., Thiry A., et al. Liver abnormalities in severely obese subjects. effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22 (1998) 222-226
8. Palmer M., and Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99 (1990) 1408-1413
9. Ueno T., Sugawara H., Sujaku K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27 (1997) 103-107
10. Abdelmalek M.F., Angulo P., Jorgensen R.A., et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis. results of a pilot study. Am J Gastroenterol 96 (2001) 2711-2717
11. Basaranoglu M., Acbay O., and Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 31 (1999) 384
12. Caldwell S.H., Hespenheide E.E., Redick J.A., et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96 (2001) 519-525
13. Diehl A.M. Nonalcoholic steatohepatitis. Semin Liver Dis 19 (1999) 221-229
14. Hasegawa T., Yoneda M., Nakamura K., et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis. a pilot study. Aliment Pharmacol Ther 15 (2001) 1667-1672
15. Laurin J., Lindor K.D., Crippin J.S., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis. a pilot study. Hepatology 23 (1996) 1464-1467
16. Lavine J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children. a pilot study. J Pediatr 136 (2000) 734-738
17. Marchesini G., Brizi M., Bianchi G., et al. Metformin in non-alcoholic steatohepatitis. Lancet 358 (2001) 893-894
18. Bays H., and Dujovne C. Pharmacotherapy of obesity. currently marketed and upcoming agents. Am J Cardiovasc Drugs 2 (2002) 245-253
19. Kelley D.E., Kuller L.H., McKolanis T.M., et al. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 27 (2004) 33-40
20. O'Meara S., Riemsma R., Shirran L., et al. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 5 (2004) 51-68
21. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study. a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27 (2004) 155-161
22. Brunt E.M. Nonalcoholic steatohepatitis. definition and pathology. Semin Liver Dis 21 (2001) 3-16
23. Harrison S.A., Ramrakhiani S., Brunt E.M., et al. Orlistat in the treatment of NASH. a case series. Am J Gastroenterol 98 (2003) 926-930
24. Harrison S.A., Fincke D., Helinski S., et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 20 (2004) 623-628
25. Griffin M.E., Marcucci M.J., Cline G.W., et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48 (1999) 1270-1274
26. Kelley D.E., Williams K.V., Price J.C., et al. Plasma fatty acids, adiposity, and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus. J Clin Endocrinol Metab 86 (2001) 5412-5419
27. Kim J.K., Fillmore J.J., Chen Y., et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98 (2001) 7522-7527
28. Ryysy L., Hakkinen A.M., Goto T., et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49 (2000) 749-758
29. Santomauro A.T., Boden G., Silva M.E., et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48 (1999) 1836-1841
30. Vozarova B., Stefan N., Lindsay R.S., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51 (2002) 1889-1895
31. Michael M.D., Kulkarni R.N., Postic C., et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6 (2000) 87-97
32. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 1705-1725
33. Saverymuttu S.H., Joseph A.E., and Maxwell J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 292 (1986) 13-15